Methods: Twenty-five NASH patients confirmed histologically, and 14 healthy

controls were enrolled in this study with patients’ consent approved by ethical committees. The serum levels of stem cell factor 1 (SCF-1), stem cell growth factor β (SCGF-β), stromal cell-derived factor 1a (SDF-1a), MCP-1, G-CSF, IL-6, IL-10, leptin, and ghrelin measured by fluorescent beads-based immunoassay, were compared Enzalutamide mw with NASH activity (NAS), the grade of fibrosis by Brunt’s classification and the appearance of HPC. Besides conventional histological observation, immunohistochemistry (IHC) and electron microscopy (EM) were conducted. The following cell markers were used; CD68 for Kupffer cell, CD34 for endothelial cells, vimentine and a-SMA for stellate cells, and CK19 /OV-6 for HPC. Results: Any laboratory data (AST, ALT, γGT, total cholesterol (TC), HDL-C, LDL-C, triglyceride, and HbA1c) were not correlated with NAS activity, and the grading of fibrosis. Among the serum levels of 9 cytokines, SDF-1a, SCGF-β, MCP-1, G-CSF and leptin was significantly higher than that in controls. Especially SDF-1α was 256.8 ± 190.1 pg/ml Autophagy Compound Library vs. 95.3 ± 73.2 (p = 0.001); SCGF-β 18,600 ± 12,764 pg/ml vs. 11,987 ± 6,967 (p = 0.001). The correlation between the SDF-1a, SCGF-β and MCP-1, and NAS activity were significantly observed r = 0.340 (p = 0.034), r = 0.345 (p = 0.032),

r = 0.484 (p = 0.002), respectively. The correlation between SDF-1a and the grade of fibrosis was r = 0.575 (p < 0.001), but SCGF-β and MCP-1 were not significant. Next, as to SDF-1a, the raw data in each patient were compared with the

appearance of HPC. The serum level of SDF-1a over 350 pg/ml was seen in most patients in stage III-IV NASH liver showing appearance of HPC characterized by small size, oval shape, and high nucleo/cytoplasm ratio by EM. Conclusions: The serum level of SDF-1α is correlated with the grade of fibro-sis and suggested the appearance of HPC. SDF-1α may be a useful marker to detect NASH patients with the advanced stage of fibrosis with the appearance of HPC, and to apply for the evaluation of pharmacological effect. Disclosures: The following people have nothing MCE公司 to disclose: Wataru Ando, Hiroaki Yokomori, Yutaka Inagaki, Isao Okazaki, Yutaka Suzuki, Tsutsui Nobuhiro, Eigoro Yama-nouchi, Hiroki Tanabe, Hajime Kuroda, Soichi Kojima, Mitsuko Hara, Masaya Oda, Takako Komiyama Background: Type 2 diabetes is strongly associated with nonalcoholic fatty liver disease and its severity. The current American guidelines do not support fatty liver screening in diabetic patients because of uncertainties surrounding screening tools. With new development in non-invasive tests, it is now possible to accurately assess hepatic steatosis and fibrosis in a large number of patients.